Immunomedics watched its shares make a massive gain on Friday after the company announced the termination of its licensing deal with Seattle Genetics.
Chris Lange 2017 could be different for the health care sector. It is very possible that this new administration could lead to more positive trials, FDA approvals, and mergers and acquisitions.
Seattle Genetics shares were down double-digits after the company announced that the FDA has placed holds on several early-stage clinical trials of its leukemia drug candidate.
Jon C. Ogg Monday’s top analyst upgrades, downgrades and initiations include Advanced Micro Devices, CVS Health, ConocoPhillips, EOG Resources, Seattle Genetics and WebMD.
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include AK Steel, Celgene, Darden Restaurants, Delphi Automotive, Johnson & Johnson and U.S. Steel.
After a dramatic conclusion to the presidential race, insider buying was dramatically larger than we have seen in months, and it could continue the rest of the year.
RBC thinks investors can buy these biotech stocks now, because the timing in their view is irrelevant, and they see the stocks de-risked and having mergers and acquisitions potential.
Lee Jackson Despite the wild ride the markets have taken, the faith of insiders certainly has not been shaken. It is indeed a positive to see insiders buying shares at current levels.
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Apple, AT&T, Autodesk, Bluebird Bio, Monsanto and Sarepta Therapeutics.
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Apple, BP, SunPower, Twitter, United Technologies , Linear Technologies and Analog Devices.
With the quarter winding down, so to are the windows for insiders to make transactions before earnings are reported. We saw a definite volume drop this week.
After a week when the indexes finally fought their way back to even for 2016, one probably would think that insiders would be selling the huge rally. Just the opposite happened.
While the insider buying wasn’t as prolific as what we saw when the market was getting pummeled in January and February, it remains consistent.
Insiders at major companies continue to shell out big bucks to buy shares, and despite the recent rally in the indexes, they don’t look they are ready to quit purchasing any time…
Maybe, just maybe, investors are starting to see the light at the end of the tunnel, and it’s not the selling train that has run shareholders over since the start of 2016.
